J. Kellogg Parsons, MD, MHS, FACS

J. Kellogg Parsons, MD, MHS, FACS

San Diego, California

UC San Diego Health System

Dr. Parsons is Professor of Urology, Endowed Chair in Clinical Research, and Director of Genitourinary Clinical and Translational Research in the Department of Urology at the Moores UC San Diego Comprehensive Cancer Center. His research focuses on prostate cancer, benign prostatic hyperplasia (BPH), and patient safety. He is a principal investigator for multi-center clinical trials funded by the National Cancer Institute (NCI) and the Department of Defense. He is an author on over 130 peer-reviewed publications, including papers in The New England Journal of Medicine, The Journal of the American Medical Association, and European Urology. He is an Associate Editor for Prostate Cancer Prostatic Diseases and a consulting editor for European Urology. Dr. Parsons is vice-chair of the National Comprehensive Cancer Network (NCCN) Panel on Prostate Cancer Early Detection and chair of the GU Surgery Committee of the NCI Alliance for Clinical Trials in Oncology. He serves on the AUA Clinical Guidelines Panel for BPH and the national Practice Guidelines Panel for the American Society of Clinical Oncology (ASCO). Dr. Parsons’ surgical practice focuses on prostate cancer, bladder cancer, and complex BPH. He has expertise in robotic prostatectomy, MRI-guided prostate biopsy, and MRI-guided focal therapy. He has been peer-elected to the America’s Best Doctors® and the San Diego Medical Society Top Doctors lists for several years. Dr. Parsons is also the award-winning author of the acclaimed novels DOING HARM (St. Martin's Press, 2014) and UNDER THE KNIFE (St. Martin's Press, 2017). For more on Dr. Parsons’ novels, visit http://kellyparsonsbooks.com.

Articles by J. Kellogg Parsons, MD, MHS, FACS

Prostate Cancer Screening & Genetic Testing: The NCCN Perspective

J. Kellogg Parsons, MD, MHS, discusses the rationale behind the National Comprehensive Cancer Network (NCCN) guidelines on prostate cancer screening and how they fit in with currently available genetic testing. He describes the multi-disciplinary makeup of the NCCN, details considerations that led to their recommendations on when men should be screened and in which circumstances, and outlines opportunities to improve the guidelines through standardization, coordination with other organizations, and improved treatment algorithms.

Read More

Diet and Prostate Cancer- Now What?

J. Kellogg Parsons, MD, MHS, FACS, reviews the Men’s Eating and Living (MEAL) study, a randomized, phase III clinical trial testing diet intervention in prostate cancer patients under active surveillance. He describes the trial methodology and design, as well as clinical progression and quality of life outcomes.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -